Can Japan’s Richest Person Save Cell Therapy’s Future?

Yanai Donates $30m To New iPSC Production Facility

With financial help from the founder of Uniqlo, Japan’s leading facility for induced pluripotent stem cells is aiming to automate production to slash costs and kick-start R&D in the field.

Japan iPSC lab
New Japan production facility aims to lower cost of induced pluripotent stem cell therapies. (Shutterstock/AI-generated)

A new facility in Japan for the production of autologous induced pluripotent stem cells (iPSCs) may help drive national R&D activities in the autologous cell therapy area by reducing both safety risks and costs, the country’s leading research foundation in the field is predicting.

Receiving a donation totaling JPY4.5bn ($30m) from the country’s richest individual, the new facility is hopeful it can reduce production...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from Cell Therapies

More from Business

BREAKING NEWS: Merck & Co. Leaps Into COPD Space With $10bn Verona Buy

 
• By 

The UK firm's chronic obstructive pulmonary drug Ohtuvayre has been enjoying a stellar launch.

Wave of Biopharma Licensing Deals in India: ‘The Model Is Working’

 

From vonoprazan and inclisiran to nirsevimab, big pharma has licensed several products to Indian firms as have other biopharma players. Experts discuss the intricacies of such licensing deals amid signs of more action in store and whether geopolitics could dull partnering with Chinese firms.

Actithera Raises $75m To Enter Competitive FAP-Targeting Radioligand Field

 

While companies such as Eli Lilly and Roche have faced setbacks to their fibroblast activation protein-targeting oncology therapies, Actithera believes its radiopharmaceuticals platform will prove more successful.